STSu'AN Tang

Su'AN Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Su'AN Tang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Temporal Trends and Cross‐Country Inequalities in the Burden of Osteoarthritis, 1990–2021: Findings From the Global Burden of Disease Study 2021

    by Haowei Chen, Lei Si, Lei Zhang, David J. Hunter, Vicky Duong, Xiaomeng Wang, Peihua Cao, Han Cen, Su'AN Tang, Tianyu Chen, et al.

    Aim: This study aimed to assess the long‐term trends in cross‐country inequalities related to the burden of osteoarthritis from 1990 to 2021. Methods: Data on osteoarthritis incidence, prevalence, years lived with disability, and sociodemographic index (SDI) were extracted from the Global Burden of Diseases Study 2021. Slope index of inequality and concentration index were calculated to quantify the absolute and relative cross‐country inequalities in osteoarthritis burden. Joinpoint regression was used to measure the average annual percentage change. Decomposition analysis was applied to quantify the contributions of population growth, population aging, and epidemiological changes to changes in osteoarthritis burden. Results: Globally, more than 600 million people had osteoarthritis in 2021, with an increase of 137.03% since 1990. Significant absolute and relative SDI‐related inequalities in osteoarthritis burden were observed across 204 countries/territories, with the burden disproportionately concentrated among countries/territories with higher SDI rankings. The slope index of inequality for all‐age osteoarthritis prevalence rose from 5759.73 to 11151.93, while the concentration index increased from 0.26 to 0.28 from 1990 to 2021. Sensitivity analyses using age‐standardized rates showed that the direction of inequality remained unchanged, whereas the increasing trend was attenuated for total osteoarthritis and persisted for knee osteoarthritis and other types of osteoarthritis. Population growth was the largest contributor to the increase in osteoarthritis burden, and population aging became the second‐largest contributor globally after 2011. Conclusions: Osteoarthritis is a growing health problem with widening cross‐country inequalities, suggesting an urgent need to adopt specific measures according to different levels of sociodemographic development.

  • The Comorbidity Burdens of Osteoarthritis and 174 Diseases, 1990–2021: A Modeling Study Based on the Global Burden of Disease Study 2021

    by Haowei Chen, Qin Dang, Yongbin Shi, David J. Hunter, Xiaomeng Wang, Hao Yang, Lei Si, Vicky Duong, Mengdi Zhang, Zhiqiang Wang, et al.

    Aim: Using data from the Global Burden of Disease (GBD) Study 2021, this study aims to estimate the comorbidity burdens of osteoarthritis (OA) at global, regional, and national levels from 1990 to 2021. Methods: The age‐standardized prevalence and years lived with disability (YLD) rate for OA and 174 other Level‐3 diseases from 204 countries and territories were extracted. A modified formula was employed to determine the comorbidity burdens for the co‐occurrence of OA and one of the other 174 diseases. Cluster analysis was performed to identify different patterns in the comorbidity burden. Results: Globally, the top three comorbidity burdens for OA in 2021 were from oral disorders, headache disorders, and age‐related and other hearing loss (age‐standardized comorbidity YLD rates 130.80/100 000, 124.09/100 000, and 79.54/100 000, respectively). From 1990 to 2021, the age‐standardized comorbidity YLD rates for diabetes mellitus exhibited the greatest increases, with percentage changes of 108.41%. In high socio‐demographic index (SDI) regions, the leading comorbidity burdens for OA were from headache disorders, oral disorders, and low back pain, whereas in low SDI regions, they were oral disorders, dietary iron deficiency, and headache disorders. Six clusters were identified, including oral disorders and headache disorders in the highest comorbidity burden with a mild changing cluster, and diabetes mellitus in the high comorbidity burden with a rapid growth cluster. Conclusions: The comorbidity burdens of OA have increased and show different patterns. These findings underscore the importance of addressing the comorbidity burdens in conjunction with tackling the OA burden.


  • Top Cited Papers

    Osteoarthritis

    by Su’an Tang, Changqing Zhang, Win Min Oo, Kai Fu, May Arna Risberg, Sita M. Bierma-Zeinstra, Tuhina Neogi, Inoshi Atukorala, Anne-Marie Malfait, Changhai Ding, et al.

    Osteoarthritis is a heterogeneous whole-joint disease that can cause pain and is a leading cause of disability and premature work loss. The predominant disease risk factors - obesity and joint injury - are well recognized and modifiable. A greater understanding of the complex mechanisms, including inflammatory, metabolic and post-traumatic processes, that can lead to disease and of the pathophysiology of pain is helping to delineate mechanistic targets. Currently, management is primarily focused on alleviating the main symptoms of pain and obstructed function through lifestyle interventions such as self-management programmes, education, physical activity, exercise and weight management. However, lack of adherence to known effective osteoarthritis therapeutic strategies also contributes to the high global disease burden. For those who have persistent symptoms that are compromising quality of life and have not responded adequately to core treatments, joint replacement is an option to consider. The burden imparted by the disease causes a substantial impact on individuals affected in terms of quality of life. For society, this disease is a substantial driver of increased health-care costs and underemployment. This Primer highlights advances and controversies in osteoarthritis, drawing key insights from the current evidence base.


  • Top Cited Papers

    Single-cell atlas of human infrapatellar fat pad and synovium implicates APOE signaling in osteoarthritis pathology

    by Su’aN Tang, Lutian Yao, Jianzhao Ruan, Jingliang Kang, Yumei Cao, Xiaoyu Nie, Weiren Lan, Zhaohua Zhu, Weiyu Han, Yongguang Liu, et al.

    The infrapatellar fat pad (IPFP) and synovium play essential roles in maintaining knee joint homeostasis and in the progression of osteoarthritis (OA). The cellular and transcriptional mechanisms regulating the function of these specialized tissues under healthy and diseased conditions are largely unknown. Here, single-cell and single-nuclei RNA sequencing of human IPFP and synovial tissues were performed to elucidate the cellular composition and transcriptional profile. Computational trajectory analysis revealed that dipeptidyl peptidase 4 + mesenchymal cells function as a common progenitor for IPFP adipocytes and synovial lining layer fibroblasts, suggesting that IPFP and synovium represent an integrated tissue unit. OA induced a profibrotic and inflammatory phenotype in mesenchymal lineage cells with biglycan + intermediate fibroblasts as a major contributor to OA fibrosis. Apolipoprotein E (APOE) signaling from intermediate fibroblasts and macrophages was identified as a critical regulatory factor. Ex vivo incubation of human cartilage with soluble APOE accelerated proteoglycan degeneration. Inhibition of APOE signaling by intra-articular injection of an anti-APOE neutralizing antibody attenuated the progression of collagenase-induced OA in mice, demonstrating a detrimental effect of APOE on cartilage. Our studies provide a framework for designing further therapeutic strategies for OA by describing the cellular and transcriptional landscape of human IPFP and synovium in healthy versus OA joints.


  • The lncRNA PILA promotes NF-κB signaling in osteoarthritis by stimulating the activity of the protein arginine methyltransferase PRMT1

    by Su’aN Tang, Yumei Cao, Zhaopeng Cai, Xiaoyu Nie, Jianzhao Ruan, Zuoqing Zhou, Guangfeng Ruan, Zhaohua Zhu, Weiyu Han, Changhai Ding

    Inflammatory cytokine–induced activation of nuclear factor κB (NF-κB) signaling plays a critical role in the pathogenesis of osteoarthritis (OA). We identified PILA as a long noncoding RNA (lncRNA) that enhances NF-κB signaling and OA. The abundance of PILA was increased in damaged cartilage from patients with OA and in human articular chondrocytes stimulated with the proinflammatory cytokine tumor necrosis factor (TNF). Knockdown of PILA inhibited TNF-induced NF-κB signaling, extracellular matrix catabolism, and apoptosis in chondrocytes, whereas ectopic expression of PILA promoted NF-κB signaling and matrix degradation. PILA promoted PRMT1-mediated arginine methylation of DExH-box helicase 9 (DHX9), leading to an increase in the transcription of the gene encoding transforming growth factor β–activated kinase 1 (TAK1), an upstream activator of NF-κB signaling. Furthermore, intra-articular injection of an adenovirus vector encoding PILA triggered spontaneous cartilage loss and exacerbated posttraumatic OA in mice. This study provides insight into the regulation of NF-κB signaling in OA and identifies a potential therapeutic target for this disease.


  • Open Access

    Inflammatory phenotype of osteoarthritis and its potential therapies

    by Yumei Cao, Su'AN Tang, Changhai Ding

    Introduction: Osteoarthritis (OA) is the most common joint disorder in the world but there are no approved therapies to slow disease progression. Historically, OA has been considered a wear and tear joint disease and efforts to identify and develop disease modifying therapies have primarily focused on inhibiting cartilage degradation directly. However, increasing studies have suggested that inflammation is a key player of joint pathology in some OA patients and also a link between obesity and OA. Therefore, targeting inflammation in these patients could be a promising therapeutic strategy.Areas Covered: In this review, we collate the latest evidence on the relationship between inflammation and OA which allows to propose the inflammatory phenotype of OA, and summarize major results of some emerging therapies targeting this phenotype in clinical trials which could implicate future directions for OA treatment.Expert Opinion: The authors believe early diagnosis, phenotyping OA patients and precise therapies would expedite the development of DMOADs targeting OA inflammatory phenotype. In the future, well‐designed clinical trials including appropriate subgroups or phenotypes of patients according to underlying causes and mechanisms of OA are expected for investigational therapies.